FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date

Once-daily Precision Timed Release™ (PTR™) stimulant designed to deliver rapid onset of effect and entire active-day duration ...

ADHD Drugs Do Much More Than Help You Focus, Study Reveals

Globally, about 5 percent of children and 2.5 percent of adults have ADHD. For many, the way their brains work means they ...
Stocktwits on MSN

Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential

Retail chatter around Cingulate picked up on Tuesday after Roth Capital Partners raised its price target to $17 from $10 and ...

FDA Stayed Silent As Internal Reports About Potential Tylenol Risks Piled Up

The Food and Drug Administration (FDA) defied the advice of its own drug safety experts to warn pregnant women about Tylenol ...
Neurology Advisor

Novel Dexmethylphenidate Formulation Under Review for ADHD

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for CTx-1301 for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adults.

'An urgent public health crisis': Why so many people are struggling to get medicine

Doctors and pharmaceutical experts have raised growing concerns about the shortages in recent months. The American Medical ...

Tylenol’s maker pushes back against possible label change linking pain reliever’s use in pregnancy to autism

Kenvue, the American company that makes Tylenol, says the US Food and Drug Administration should not make proposed changes to ...
Health and Me on MSN

FDA Considers Autism Warning on Tylenol; Maker Raises Concerns

Kenvue, the maker of Tylenol, is pushing back against an FDA proposal to update its safety label with a potential link ...